We have uncovered a conserved role of SUMOylation in transcriptional silencing of the MHC-I/APM pathway and expand the understanding of SUMO inhibition (SUMOi) as a rational therapeutic strategy to improve efficacy of cancer immunotherapies. Here, ANPEP is linked to cancer.